Phathom Pharmaceuticals, Inc.PHATNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P13
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | -6.18% |
| Q3 2025 | -39.57% |
| Q2 2025 | -9.70% |
| Q1 2025 | 23.20% |
| Q4 2024 | 0.77% |
| Q3 2024 | 0.30% |
| Q2 2024 | 22.35% |
| Q1 2024 | 9.15% |
| Q4 2023 | 144.09% |
| Q3 2023 | 22.91% |
| Q2 2023 | 1.82% |
| Q1 2023 | -39.08% |
| Q4 2022 | 30.83% |
| Q3 2022 | -12.11% |
| Q2 2022 | 31.96% |
| Q1 2022 | 3.24% |
| Q4 2021 | 17.90% |
| Q3 2021 | 20.46% |
| Q2 2021 | 5.52% |
| Q1 2021 | 20.57% |
| Q4 2020 | 52.76% |
| Q3 2020 | 36.77% |
| Q2 2020 | 14.46% |
| Q1 2020 | 50.89% |
| Q4 2019 | 64.86% |
| Q3 2019 | 34.80% |
| Q2 2019 | 68.76% |
| Q1 2019 | 82.38% |
| Q4 2018 | 66.79% |
| Q3 2018 | 3.56% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |